Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Short Interest Update

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) was the target of a large decrease in short interest during the month of December. As of December 31st, there was short interest totalling 13,300 shares, a decrease of 50.9% from the December 15th total of 27,100 shares. Currently, 2.4% of the company’s stock are short sold. Based on an average trading volume of 652,600 shares, the short-interest ratio is currently 0.0 days.

Bluejay Diagnostics Stock Performance

Shares of Bluejay Diagnostics stock traded down $0.11 on Tuesday, reaching $3.55. The stock had a trading volume of 12,453 shares, compared to its average volume of 84,032. The business’s 50-day moving average price is $4.12 and its two-hundred day moving average price is $11.01. The stock has a market cap of $1.96 million, a P/E ratio of 0.00 and a beta of 0.48. Bluejay Diagnostics has a fifty-two week low of $3.03 and a fifty-two week high of $419.64.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Bluejay Diagnostics stock. CVI Holdings LLC acquired a new position in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 66,165 shares of the company’s stock, valued at approximately $46,000. CVI Holdings LLC owned 19.69% of Bluejay Diagnostics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 18.47% of the company’s stock.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.